All In Biotech

Drug Trial Radar · NCT06597565

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

A Phase II Study of ACR-368 and Low Dose Gemcitabine Combination Therapy in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

43

Planned (sponsor's estimate)

Start

Sep 25, 2024

Primary completion

Aug 23, 2028

Study completion Aug 23, 2028

Sponsor

Lead sponsor
H. Lee Moffitt Cancer Center and Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Acrivon Therapeutics
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine the activity and safety of ACR-368 (prexasertib) in combination with gemcitabine in participants with Head and Neck Squamous Cell Carcinoma (HNSCC). Participants will receive the study drugs ACR-368 and a low dose of gemcitabine once every 2 weeks in 4-week cycles and will continue on treatment unless the disease deteriorates.

Conditions

  • Head and Neck Squamous Cell Carcinoma

Interventions

  • GemcitabineDrug

    Gemcitabine is a standard of care given at ultralow dose in combination with the experimental drug ACR-368.

  • ACR-368Drug

    ACR-368 is an experimental drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate: Cohort ATime frame: Up to 24 Months
  2. Overall Response Rate: Cohort BTime frame: Up to 24 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.